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The occurrence of endothelial alterations in the liver and in the splanchnic vasculature of cir-
rhotic patients and experimental models of liver diseases has been demonstrated. However,
the pathological role of the portal vein endothelium in this clinical context is scarcely studied
and, therefore, deserves attention. In this context, we aimed to investigate whether patho-
logical endothelial activation occurs in the portal vein of cirrhotic rats.
Methods
Cirrhosis was induced in wistar rats by CCl4 inhalation. We generated immortalized endo-
thelial cells from the portal vein of control (CT-iPVEC) and cirrhotic rats (CH-iPVEC) by ret-
roviral transduction of the SV40 T antigen. We assessed differential gene expression and
intracellular reactive oxygen species (ROS) levels in iPVECs and in portal veins of control
and cirrhotic rats. Finally, we assessed the therapeutic effectiveness of cerium oxide nano-
particles (CeO2NP) on reversing PVEC activation and macrophage polarization.
Results
CH-iPVECs overexpressed collagen-I, endothelin-1, TIMP-1, TIMP-2, IL-6 and PlGF genes.
These results were consistent with the differential expression showed by whole portal veins
from cirrhotic rats. In addition, CH-iPVECs showed a significant increase in intracellular
ROS and the capacity of potentiating M1 polarization in macrophages. The treatment of CH-
iPVECs with CeO2NPs blocked intracellular ROS formation and IL-6 and TIMP-2 gene over-
expression. In agreement with the in vitro results, the chronic treatment of cirrhotic rats with
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CeO2NPs also resulted in the blockade of both ROS formation and IL-6 gene overexpres-
sion in whole portal veins.
Conclusions
Endothelial cells from portal vein of cirrhotic rats depicted an abnormal phenotype charac-
terized by a differential gene expression and the induction of M1 polarization in macro-
phages. We identified the excess of intracellular reactive oxygen species (ROS) as a major
contributor to this altered phenotype. In addition, we demonstrated the utility of the nanoma-
terial cerium oxide as an effective antioxidant capable of reverse some of these pathological
features associated with the portal vein in the cirrhosis condition.
Introduction
The portal vein carries blood from the gastrointestinal track to the liver contributing to the
~70% of the hepatic blood volume. This anatomical arrangement causes that the concentra-
tions of certain hormones, metabolites and in some cases toxics xenobiotics are comparatively
higher in the hepatic portal circulation than in any other vascular territory [1,2]. The exposure
of the portal vein to this portal circulatory environment may result in the vascular activation of
proinflammatory immune modulators that eventually may contribute to the development or
worsening of portal hypertensive syndromes. For instance, the diseases most commonly
encountered in the group of non-cirrhotic portal hypertensive syndromes are idiopathic portal
hypertension and extrahepatic portal vein thrombosis and although the etiology of both
pathologies are unclear it is considered to be pre-hepatic and vascular in origin with a signifi-
cant pro-inflammatory component [3,4]. The pathological role of the portal vein in cirrhotic
portal hypertensive syndromes has also been described in some contexts such as alcoholic cir-
rhosis. The resistance to portal blood flow in these patients is predominantly sinusoidal, but
vascular remodeling of the portal vein also contribute to the overall intrahepatic resistance
[5,6]. Based on these observations, we hypothesized that alterations in the functional properties
of the portal vein may occur in portal hypertensive syndrome and that the pathophysiological
characterization of this vascular bed is clinically relevant.
A normofunctional endothelium is crucial for the maintenance of vascular integrity
through its anti-coagulant, anti-inflammatory and vasodilatory properties. However, several
studies showed that the vascular endothelium may change to an activated/dysfunctional phe-
notype characterized by its pro-coagulant, pro-inflammatory and vasoconstrictive properties
[7–11]. Endothelial cell activation has been documented in liver sinusoids in the context of
chronic liver diseases [12–17]. However, very few publications have investigated the pathologi-
cal role of the endothelial cell activation in other vascular areas such as the portal vein. A key
limitation of this research field is the lack of established cell lines and the low-throughput char-
acteristics of the classical cell isolation methods used to isolate endothelial cells from this vas-
cular territory. In our study, we overcome this limitation by isolating primary endothelial cells
from the portal vein of control and cirrhotic rats and immortalizing them by retroviral trans-
duction of the SV40 large T antigen (iPVEC). The objectives of our study were 1) to character-
ize the differential phenotype of iPVECs after the establishment of these cell lines, 2) to
correlate the cellular in vitro findings with the in vivo abnormalities of the portal vein in con-
trol and in cirrhotic rats and 3) to identify key molecular mechanisms responsible for switch-
ing the endothelium of the portal vein from a normofunctional to a dysfunctional state.
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Here we show that endothelial cells from portal vein of CH rats depicted an abnormal phe-
notype characterized by a differential gene expression of proinflammatory, vasoactive and
extracellular matrix remodeling genes. In addition, these cells showed a differential secretome
and the capacity of potentiating M1 polarization in macrophages. We identified intracellular
oxidative stress as a major contributor to this altered phenotype and evaluated the therapeutic
utility of cerium oxide nanoparticles to revert the abnormalities found in the portal vein endo-
thelium of cirrhotic rats.
Materials and methods
Experimental model of fibrotic rats
This study was performed in male adult Wistar rats with liver fibrosis (CCl4-treated rats) and
control (CT) Wistar rats (Charles–River, Saint Aubin les Elseuf, France). Liver fibrosis was
induced by inhalation of CCl4, as has previously been described [18]. All the animals were
housed in 595×380×200 mm cages (Techniplast UK, 1354G Eurostandard Type IV) and were
kept under constant temperature and humidity in a 12-h controlled dark/light cycle. The rats
were fed ad libitum on a standard pellet diet. Control rats and CCl4-treated rats were studied
20 weeks after the start of the fibrosis induction protocol. During housing, animals were moni-
tored twice daily for health status. No adverse events were observed. All animal procedures
were approved by the Investigation and Ethics Committee of Animal Experimentation of the
University of Barcelona.
Isolation and immortalization of PVECs
Portal veins were isolated and digested with a 0.25% solution of collagenase A (Roche, Mann-
heim, Germany). Primary PVECs were isolated from the portal vein of control and cirrhotic
(CH) rats using a rabbit anti-rat CD31 antibody (Abbiotec, San Diego, CA, USA) and mag-
netic beads coupled with a goat anti-rabbit secondary antibody (MACS system, Miltenyi Bio-
tec, Germany). The immortalization of the endothelial cells was performed when the cells
reached 75% of confluence by retroviral transduction of the middle T antigen from the SV40
virus and a geneticin resistance gene. After retroviral transduction, cells were maintained in
Endothelial Cell Growth Medium 2 (Promocell, Heidelberg, Germany) supplemented with 50
U/mL penicillin, 50 μg/mL streptomycin and 10% fetal calf serum (FBS).
Flow cytometry
Purity of endothelial cells was assessed by flow cytometry. First, cells were washed and re-sus-
pended in PBS supplemented with 5% heat-inactivated FBS. A rabbit anti-rat CD31 (Abbiotec,
San Diego, CA, USA) was used as a primary antibody. Then, cells were labeled using Alexa-
488 conjugated anti-Rabbit secondary antibody (Life Technologies, Carlsbad, CA, USA). Posi-
tive cells were detected on a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA,
USA) and analyzed using FACSdiva software (BD Biosciences, San Jose, CA, USA). The nega-
tive population for the CD31 antigen was chosen from cells quantified in the absence of anti-
CD31 antibody.
Characterization and quantification of CeO2NP
CeO2NPs, with an average diameter of 4–20 nm, were synthesized by the chemical precipita-
tion of cerium (III) nitrate hexahydrated (Sigma-Aldrich, St. Louis, MO, USA) as previously
described [19,20]. High resolution Transmission Electron Microscopy (HR-TEM) was per-
formed using a JEOL-1010 TEM (JEOL, Tokyo, Japan) with the field-emission gun operating
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at 80 kV. Prior to the analysis, 15μL from the nanoparticles solution were dispersed on a cop-
per grid coated with a formvar film. The samples were then let to dry for TEM observation and
digital photomicrographs were taken (BioScan Gatan, CA, USA). Cerium concentration in tis-
sue was measured by inductively coupled plasma mass spectrometry (ICP-MS, Agilent 7500;
Agilent Technologies CA, USA). The quantification is performed by interpolation in a stan-
dard curve obtained from a commercial 1000 ppm Ce standard (Sigma-Aldrich, St. Louis, Mis-
suori, USA).
In vivo and in vitro studies with CeO2NPs treatment
For the in vivo study, control and cirrhotic rats were randomly distributed into two groups.
One group was treated with 0.1 mg/kg of CeO2NPs in TmaOH 0.8mM (n = 20 for each experi-
mental condition) and CCl4 treatment was maintained thereafter. The second group received
vehicle (saline solution containing TMAOH ammonium salts 0.8 mM) (n = 20 for each experi-
mental condition). CeO2NPs were dispersed in saline solution and intravenously given as a
bolus (500 μL) through the tail vein. For the intravenous injection, animals were initially
anaesthetized under a 5% of isoflurane inhalation and then maintained under 2–2.5% isoflur-
ane for the rest of the procedure, with an oxygen flow rate of 800 cc/min. The treatments were
administered twice per week for two weeks. At the end of the treatments, rats were euthanized
by anaesthesia overdose (5% of isoflurane inhalation in oxygen) and organs dissected and kept
at -80 ºC for further analysis.
For the in vitro study, cells were treated with CeO2NPs (1μg/mL) for 24 hours in a water-
jacketed CO2 incubator (Forma Scientific Series II, 3131, Marietta, OH).
Scanning electron microscope (SEM)
Portal vein samples were fixed in 2% paraformaldehyde and 2.5% gluteraldehyde for further
ultrastructural examination. Next, each sample was ion-sputter-coated and observed at low
electron power microscope to increase contrast in a Jeol JSM 5600 LV scanning electron
microscope (Jeol Ltd., Tokyo, Japan) equipped with a BioScan camera (Gatan, CA, USA), and
digital photomicrographs were taken.
Macrophage differentiation
Briefly, femurs from rats aged 8 to 10 weeks were flushed and bone marrow derived cells were
collected by centrifugation at 450×g for 5 min at 4˚C. Cells were then re-suspended in DMEM,
supplemented with 10% heat-inactivated FBS and 30% of L-929 M-CSF conditioned medium,
and cultured at a density of 1×106 cells/mL in non-tissue culture treated plastic dishes (BD Bio-
sciences, San Jose, CA, USA) in a humidified atmosphere (95% air, 5%CO2) at 37˚C. Medium
was replaced every 2 days. After 6 days, adherent cells were collected and cell viability was mea-
sured by trypan blue. Bone marrow derived macrophages (BMDM) were then diluted in
DMEM containing 10% of heat-inactivated FBS and plated in culture dishes for further
experiments.
Generation of M-CSF containing conditioned medium
M-CSF overexpressing L929 cells were kindly donated by Prof. Antonio Celada (Macrophage
Biology Group, School of Biology-University of Barcelona). Cells were cultured up to a 75% of
confluence in DMEM supplemented with 2% of heat-inactivated FBS, 50 U/ml penicillin and
50 μg/ml streptomycin. After 5 days of culturing, medium was replaced keeping the collected
medium. On the tenth day, the medium was collected and mixed with the conditioned
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medium obtained at day 5. After filtration with a 0.2 μm filter, the final conditioned medium
was stored at -20ºC for later use. The concentration of M-CSF in this conditioned medium
was 5 ng/mL, according to ELISA quantification (Cusabio, Baltimore, MD, USA).
Immunocytofluorescence
The iPVECs were fixed with 4% paraformaldehyde for 10 minutes. Cells were washed three
times with PBS and permeabilized with 0.1% Triton for 4 minutes at 4˚C. Then, cells were
incubated for 1 hour with rabbit anti-rat CD31 primary antibody (Abbiotec, San Diego, CA,
USA) and anti-rabbit FITC secondary antibody (Life Technologies, Carlsbad, CA, USA) for 1
h. Immunofluorescence was visualized with a fluorescent microscope (Nikon Eclipse E600,
Kawasaki, Kanagawa, Japan).
Real-Time PCR
Total RNA was extracted from cultured PVEC using the Trizol reagent (Life Technologies,
Carlsbad, CA, USA). One microgram of total RNA was reverse transcribed using First Strand
cDNA Synthesis Kit (Roche, Mannheim, Germany). Subsequently, complementary DNA sam-
ples were amplified for 30–35 cycles (94 for 30 seconds, 55–60˚C for 30 seconds, and 72 during
1 minute; LigthCycler 480-Roche Diagnostics). To normalize the results, HPRT gene was used
as reference. Specific primers for amplification of the complementary DNA were:
Collagen I, 5'-AGACCTGGCGAGAGAGGAGT-3' (forward primer) and 5'-ATCCAGAC
CGTTGTGTCCTC-3' (reverse primer);
TIMP1, 5’-CATGGAGAGCCTCTGTGGAT-3' (forward primer) and 5'-TGTGCAAATTT
CCGTTCCTT-3' (reverse primer);
TIMP2, 5’-GACAAGGACATCGAATTTATCTACAC-3' (forward primer) and 5'-CCATC
TCCTTCCGCCTTC-3' (reverse primer);
PlGF, 5’-GTTGGCTGTGCACTCCCAG-3' (forward primer) and 5'-GTTGGCTGTGCAC
TCCCAG-3' (reverse primer);
Endothelin-1, 5'-CTCCTCCTTGATGGACAAGG-3' (forward primer) and 5'-CTTGATG
CTGTTGCTGATGG-3' (reverse primer);
IL-6, 5'-GCCCTTCAGGAACAGCTATGA-3' (forward primer) and 5'-TGTCAACAACAT
CAGTCCCAAGA-3' (reverse primer);
MMP2, 5’-GCGCTTTTCTCGAATCCAT-3' (forward primer) and 5'-GGGTATCCATCT
CCATGCTC-3' (reverse primer);
eNOS, 5’-TCTACCGGGACGAGGTACTG-3' (forward primer) and 5'-CTGTCCTCAGG
AGGTCTTGC-3' (reverse primer);
iNOS, 5’-ACAACAGGAACCTACCAGCTCA-3' (forward primer) and 5'-GATGTTGTAG
CGCTGTGTGTCA-3' (reverse primer);
TNF-α, 5’-CAAGGAGGAGAAGTTCCCAA-3' (forward primer) and 5'-CTCTGCTTGGT
GGTTTGCTA-3' (reverse primer);
Arginase-1, 5’-CAAGCTGGGAATTGGCAAAG-3' (forward primer) and 5'-GGTCCAGT
CCATCAACATCAAA-3' (reverse primer); and
HPRT, 5’-GACCGGTTCTGTCATGTCG-3' (forward primer) and 5'-ACCTGGTTCATC
ATCACTAATCAC-3' (reverse primer).
Characterization of iPVEC secretome by mass spectrometry
Protein profiling was performed by surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry (SELDI-TOF-MS) using the eight-spot format CM10 ProteinChip
arrays (Bio-Rad, Hercules, CA, USA). Conditioned cell culture media from iPVECs was loaded
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onto CM10 Protein Chip arrays. Prior to sample loading, spots were equilibrated two times
with 200 μL of CM binding/washing buffer (0.1 M sodium acetate, pH 4). Each sample was
loaded in duplicate randomly in order to minimize any systematic error. Forty microliters of
conditioned medium were incubated in 60 μL of CM binding buffer for 30 minutes on a
shaker at room temperature. Afterwards, arrays were washed three times with 200 μL CM
washing buffer for 5 minutes at room temperature. Unbound serum proteins were removed
by washing twice with deionized water. Thereafter, arrays were air-dried and 1 μL of energy-
absorbing matrix (saturated sinapinic acid in an aqueous solution containing 50% acetonitrile
and 0.5% TFA) was added twice to each spot. The surface was allowed to air dry between each
application. The array was read by using the ProteinChip PBS II reader (BioRad, Hercules,
CA, USA). Each spot was read at 3000 nJ energy laser intensity. All spectra were calibrated
using two external calibration standards (all-in-one peptide standard and all-in-one protein
standard, BioRad, Hercules, USA). A peak resolution was optimized within 5.000 m/z, 12.000
m/z or 19.000 m/z according to low, medium or high energy laser intensity, respectively.
Western blot experiments
Cell lysates were prepared in a lysis buffer (Tris–HCl 20 mM pH 7.4 containing 1% Triton X-
100, 0.1% SDS, 50 mM NaCl, 2.5 mM EDTA, 1 mM Na4P2O7 10H2O, 20 mM NaF, 1 mM
Na3VO4, 2 mM Pefabloc and Complete from Roche). Proteins were separated on a 7.5% SDS-
polyacrylamide gel (Mini Protean III, BioRad, Richmond, Ca) and transferred for 2 hours at
4ºC to nitrocellulose membrane (Transblot Transfer Medium, BioRad, Richmond, CA) that
was stained with Ponceau-S red as a control for protein loading. The membrane were incu-
bated at 4ºC with rabbit polyclonal anti-rat VE-Cadherin (Abcam plc, Cambridge, UK) over-
night in a 1:1000 dilution. Then, the membrane was incubated with goat anti-rabbit
peroxidase-conjugated secondary antibody at a 1:5000 dilution (Cell Signaling, Beverly, MA)
for 1 hour at room temperature. The bands were visualized by chemiluminescence (ECL west-
ern blotting analysis system; Amersham Biosciences).
Reactive oxygen species measurement
Fluorescence spectrophotometry was used to measure ROS, with 2’,7’-DCF-DA as the probe
(Life Technologies, Carlsbad, CA, USA). DCF-DA readily diffuses through the membrane and
is enzymatically hydrolyzed by intracellular esterases to the nonfluorescent DCFH, which can
then be rapidly oxidized to fluorescent DCF in the presence of ROS. PVECs incubated in the
presence of CeO2NPs or vehicle were washed with PBS buffer and incubated with 10 μM
DCF-DA in DMEM for 50 min at 37 ºC in the dark. The supernatant was collected to measure
the extracellular production of ROS, and the intensity of fluorescence was immediately read in
a fluorescence spectrophotometer (FLUOstar OPTIMA; BMG LABTECH, Ortenberg, Ger-
many) at 485 nm for excitation and at 520 nm for emission.
Oxidative stress present in rat portal veins was determined by malondialdehyde (MDA)
assay (ELISA) according manufacturer’s instructions (Cell Biolabs, San Diego, USA).
Statistical analysis
Quantitative data were analyzed using GraphPad Prism, version 5 (GraphPad Software, Inc.,
San Diego, CA) and public libraries from The Comprehensive R Archive Network (CRAN;
http://CRAN.R-project.org) rooted in the open source statistical computing environment R,
version 3.4 (http://www.R-project.org/). The statistical analysis of the results was performed
using unpaired Student’s t-tests and ANOVA models (with Tukey’s post hoc test) with nor-
mally distributed data. For other type of data, the Mann–Whitney U-test and the Kruskal-
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Wallis tests (with Dunn post hoc test) were used. Results are expressed as mean±s.e.m and
considered significant at a p value lower than 0.05.
Results
Generation and characterization of immortalized PVECs from portal vein
of control and cirrhotic rats
To investigate the cellular mechanisms that contribute to the portal vascular dysfunction char-
acteristic of cirrhosis, we isolated rat portal endothelial cells (PVEC) from control and cirrhotic
rats. After the immortalization procedure using middle T antigen we established two cell
clones for each experimental condition. Next, cells were tested for the maintenance of endo-
thelial cell markers. Freshly isolated PVEC maintained the characteristic cobblestone morphol-
ogy of endothelial cells (Fig 1A, panels a and b). Immortalization resulted in altered cell shape
and a lack of the directional alignment characteristic of the primary PVEC (Fig 1A, panels c
and d). Despite the change in morphology, nearly 97% of immortalized iPVEC (iPVEC) con-
served the expression of the endothelial cell markers CD31 and VE-cadherin, as assessed by
immunofluorescence (Fig 1B), flow cytometry (Fig 1C) and western blot (Fig 1D). In the case
of VE-cadherin, iPVEC from cirrhotic rats expressed lower levels of VE-cadherin compared
with control rats, suggesting that these cells have maintained part of the altered phenotype
caused by the cirrhosis condition. Alpha-smooth muscle actin (α-SMA) protein was undetect-
able in either of the immortalized iPVEC clones established from control and cirrhotic rats
(Fig 1B, panels b and e), ruling out the presence of contaminating pericytes or vascular smooth
muscle cells.
iPVEC and portal veins from cirrhotic rats showed a similar gene
expression profile and increased levels of ROS
To further investigate the possibility that iPVECs from cirrhotic rats maintained part of the
altered phenotype caused by the cirrhosis condition, we measured by real-time PCR the
expression of genes that were previously described to be differentially expressed in other vas-
cular territories due to chronic liver disease [17,18,21,22]. All of the genes that we measured in
iPVECs have known roles in inflammation (IL-6), regulation of the vascular tone and remod-
eling (collagen 1, endothelin-1, MMP2, TIMP1, TIMP2 and eNOS). Col1A1, endothelin-1,
MMP2, IL-6, TIMP1, TIMP2 and PlGF were differentially expressed in iPVECs from cirrhotic
rats (Fig 2A). All of them except MMP2 were up-regulated in the cirrhosis condition being IL-
6 the gene showing the largest extent of up-regulation. In the case of MMP2, iPVECs from cir-
rhotic rats showed a 5-fold downregulation of this gene compared with iPVECs from control
rats (Fig 2A). Unexpectedly, negligible expression of eNOS was seen in the iPVECs clones
obtained from control or cirrhotic rats.
To study the in vivo correlation of the differential expression found in iPVECs, portal veins
from control and cirrhotic rats were processed to quantify mRNA expression. The same panel
of genes was measured in whole portal vein and the result was compared with that obtained in
iPVECs. As shown in Fig 2B, portal vein from cirrhotic rats overexpressed collagen I, endothe-
lin-1, IL-6, TIMP1, TIMP2 and PlGF. This profile of overexpressed genes is consistent with
the differential expression found in iPVEC from cirrhotic rats except for MMP2, which
showed opposite mRNA changes in portal vein (~4-fold overexpression) and iPVECs (~5-fold
downregulation), compared with the control condition. The eNOS gene was also found to be
overexpressed in the portal vein of cirrhotic rats, in agreement with what have been described
in other vascular areas studied in the CCl4, BDL or PVL experimental rat models [2].
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It has been established that vascular dysfunction is closely associated with elevated produc-
tion of vascular ROS. For instance, oxidative stress up-regulates the expression of endothelin-1
[23], pro-inflammatory mediators such as IL-6 [24] and vascular remodeling factors such as
collagen 1 [25,26], which we found overexpressed in both iPVEC and portal vein from cir-
rhotic rats. Therefore, it is possible that vascular oxidative stress may be involved in the pheno-
typic switch that we observed in endothelial cells from portal veins of cirrhotic rats. In order to
verify this hypothesis, we investigated the production of reactive oxygen species in iPVEC
from both control and cirrhotic rats. We added dihydrodichlorofluorescein diacetate
(H2DCF-DA) to cells in culture to measure oxidative stress in iPVEC. H2DCF-DA accumu-
lates preferentially in the cytosol and the intracellular oxidation of H2DCF into the fluoro-
chrome DCF is measured to evaluate generalized oxidative stress. We compared the baseline
Fig 1. Immortalized PVEC maintain endothelial cell features. PVECs were isolated from portal veins from control and cirrhotic rats. Immortalization of the cells
was carried out using a retrovirus long sequence containing the SV40 virus T antigen. A Images taken by optical microscope of PVECs from control (left) and
cirrhotic (right) rats, before (top) and after (bottom) immortalization, are shown. B CD31 and α-SMA immunostainings are shown for iPVECS established from
control (a, b and c panels) and cirrhotic rats (d, e and f panels). The merged panels show CD31 and α-SMA colocalization. Nuclei were stained with DAPI (blue)
(n = 5). Original magnification 200X. C iPVECs were immunostained for CD31 and analyzed by flow cytometer. Panel a shows dot-blot graph of the cell population.
The negative population for the CD31 antigen was chosen from cells quantified in the absence of anti-CD31 antibody (panel c), CT-iPVEC (panel b), and CH-iPVEC
(panel d) (n = 5). D cell lysates were analyzed by western blot. Upper panel shows VE-Cadherin immunoblot with loading control by ponceau staining. Lower panel
shows densitometric analysis of the western blot. �p<0.05 vs control.
https://doi.org/10.1371/journal.pone.0218716.g001
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level of oxidative stress in both groups of iPVECs. As shown in Fig 3A, DCF levels were 2-fold
higher in iPVEC from cirrhotic rats compared with iPVEC isolated from control rats. Oxida-
tive stress was also measured in whole portal veins from cirrhotic and control rats by malon-
dialdehyde (MDA) quantification. In agreement with the ROS measurement in iPVECs, MDA
levels were between 3 and 6-fold higher in portal veins from cirrhotic rats compared with por-
tal veins from control rats (Fig 3B).
CeO2NPs treatment reduced oxidative stress of portal vein endothelial cells
in vitro and in vivo, and partially normalizes the endothelium
angioarchitecture in the portal vein
An important question is whether and effective anti-oxidant intervention in the portal vein
may result in a normofunctional vascular reprogrammation of the transcriptome in CCl4-
Fig 2. Comparison of gene expression profiles between CT-iPVEC and CH-iPVEC. A iPVECs established from the portal vein of control (CT-iPVEC) or
cirrhotic rats (CH-iPVEC) were lysed in trizol and their mRNA expression was analyzed by real-time PCR, as described in materials and methods. Graph show the
different expression levels for the corresponding genes. mRNA levels are illustrated as fold change relative to HPRT mRNA levels. �p<0.05 vs control (n = 10). B
Portal veins from either control or cirrhotic rats were extracted and Lysed in Trizol. mRNA expression was analyzed by real-time PCR. Graph show the different
expression levels for the corresponding genes. mRNA levels are illustrated as fold change relative to HPRT mRNA levels. �p<0.05 vs control (n = 10).
https://doi.org/10.1371/journal.pone.0218716.g002
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treated rats. With this objective in mind we treated iPVEC and cirrhotic animals with the
nanomaterial cerium oxide. Fig 3C shows the transmission electron microscopy (TEM) images
of the CeO2NPs suspension, which is characterized by a similar polyhedral shape of the nano-
particles with loose agglomerates and an average diameter of 4–20 nm.
The antioxidant activity of CeO2NPs was assessed on iPVECs by measuring the intracellular
accumulation of DCF. CeO2NPs tested in the dose range 0.1–10 μg/mL did not appear to pro-
duce any change on DCF values in iPVEC from control rats, suggesting that the baseline levels
of ROS in the iPVECs from control rats are negligible. In contrast, CeO2NPs treatment of cir-
rhotic iPVEC reduces significantly the intracellular levels of ROS at the doses from 1 to 3 μg/
mL. Specifically, CeO2NPs showed the highest scavenging activity at a concentration of 1 μg/
mL. At this optimal concentration, DCF fluorescence significantly decreased, approaching the
levels found in control iPVECs. However, cirrhotic iPVECs exposed to CeO2NPs at higher
Fig 3. Increased levels of ROS in CH-PVEC and portal vein of cirrhotic rats are reduced by CeO2NPs treatment. A HR-TEM photomicrograph of CeO2NPs
(400,000X). The suspension of CeO2NPs for HR-TEM was dispersed on a copper grid coated with a formvar film as described in material and methods. B oxidative stress
was measured in cell lines using DCF. Graph shows the oxidation level at basal and different concentrations of CeO2NPs.
�p<0.05 vs basal condition (n = 10). C oxidative
stress was measured in portal veins using MDA assay. Table shows the oxidation level expressed as pmol of MDA per mg of portal vein tissue extracted from rats treated
with vehicle or CeO2NPs (0.1 mg/kg) (n = 5). D CeO2NP treatment promoted angioarchitecture normalization in the portal vein of cirrhotic rats. Representative
scanning electron micrographs of the vascular endothelium from portal veins of control, cirrhotic and CeO2NPs treated cirrhotic rats (X 500; 15.0 kV). Arrows denote
high profusion of endothelial exfoliation with loss of cell-cell junctions. Arrow heads denote extra-vascular cell adhesion to the vascular endothelium (n = 3).
https://doi.org/10.1371/journal.pone.0218716.g003
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doses than 3 μg/mL showed a hormetic-like dose response characterized by an increasing-dose
inefficacy in ROS scavenging (Fig 3A). The direct toxic effect of CeO2NPs on iPVECs was also
evaluated with the Trypan Blue exclusion test. At the concentration tested (0.1–10 μg/mL), the
exposure of the cells with the nanoparticles did not affect cell viability.
To translate our in vitro results to the in vivo situation, we investigate whether portal vein
from cirrhotic rats reduced its oxidative stress levels in response to the chronic treatment with
CeO2NPs. After 2 weeks of CeO2NPs treatment, portal veins from both control and cirrhotic
rats retained a 7% of the total dose of nanoparticles given via tail vein injection, as measured
by inductively coupled plasma mass spectrometry (14.26 μg from the total 200 μg CeO2NPs
administered over the two-week treatment period). After the treatment, we measured the lev-
els of MDA in the portal vein from cirrhotic rats treated with CeO2NPs and we found that the
levels were negligible compared with portal vein from cirrhotic rats without treatment (Fig 3B,
last row). These findings correlated with an improvement of the endothelium monolayer in
the portal vein. Under scanning electron microscope (SEM), cirrhotic portal vein presents a
rougher and unstructured surface (Fig 3D, panel b), while these abnormalities were partially
corrected after the chronic treatment with CeO2NPs resulting in a smoother surface (Fig 3D,
panel c), more similar to the control condition (Fig 3D, panel a).
Conditioned medium from CH-iPVEC polarized macrophages to an M1
phenotype
The interaction between the endothelium and leukocytes is critical for the activation and the
recruitment of inflammatory cells. We have found that iPVEC from cirrhotic rats overex-
pressed IL-6. Considering this proinflammatory phenotype, we next investigated whether the
secretome of iPVECs from cirrhotic rats affected macrophage polarization and, therefore,
inflammatory response. For this purpose, we collected conditioned medium of iPVEC from
control and cirrhotic rats that were cultivated in presence of 2%FBS for 72 hours. The iPVEC
secretomes from each cell clone isolated from the control and the cirrhosis condition were
characterized by proteomics (SELDI-TOF mass spectrometry). As shown in Fig 4A, eight
peptidic clusters from the collected conditioned medium of the two CH-iPVEC clones
showed a significant higher intensity (m/z of 7.530, 7.715, 7.810, 7.915, 7.990, 8.010, 8.320 and
8.480 kDa), while 2 peaks (m/z of 7.500 and 8.515 kDa) showed a lower intensity when com-
pared with the CT-iPVEC conditioned media. This divergence in the secretomes of iPVEC
suggests that besides presenting a differential transcription reprogramming, iPVECs from cir-
rhotic rats may also interact differentially with their cellular environment through their
secretome.
To determine the effect of iPVECs on macrophage polarization, we exposed bone marrow
derived macrophages to conditioned medium from CT-iPVEC or CH-iPVEC for 8h. Without
any additional stimuli, conditioned medium from CH-iPVEC induced the expression of iNOS
and TNF-α in macrophages and downregulated arginase-1 (Arg-1) mRNA, compared with
conditioned medium from CT-iPVEC (Fig 4B). To investigate further the effect of iPVEC on
macrophage polarization induced by the cytokine environment, we characterized the effect of
conditional medium on the induction of M1 and M2 polarization by IFN-γ and IL-4, respec-
tively. As shown in Fig 4C, CH-iPVEC conditioned medium potentiates the effect of IFN-γ on
the induction of iNOS and TNF-α overexpression in macrophages. Consistently, we found
that macrophages exposed to CH-iPVEC showed a significant downregulation of arginase-1
mRNA after incubation with IL-4, compared with the CT-iPVEC treatment. These results
together, demonstrate the ability of the CH-iPVEC secretome to polarize macrophages toward
the M1 fate in both basal conditions and after cytokine stimulation.
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Fig 4. Characterization of iPVEC secretome and iPVEC-induced macrophage polarization. A Representative proteomic profile of
conditioned cell culture media (DMEM supplemented with 2% FBS) obtained from CT-PVEC (blue spectrogram) and CH-PVEC (red
spectrogram) after 3 days of cell culture. Graph shows a differential proteomic signature in the segment of the SELDI-TOF-MS spectra
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CeO2NPs treatment switch CH-iPVEC-induced macrophage polarization
from M1 to M2
Once we established the optimal concentration for CeO2NPs treatment, we next investigated
whether the protection against oxidative stress in iPVEC improves the altered gene expression
pattern that we previously described in the cirrhotic condition. The treatment of iPVECs with
1μg/mL CeO2NPs for 24 hours did not modify the expression of Col1A1, endothelin-1,
TIMP1, PlGF or MMP2; compared with vehicle treatment (S1 Fig). Interestingly, CeO2NPs
treatment caused a significant decrease in the expression of IL-6 and TIMP-2 in CH-iPVEC,
suggesting that oxidative stress is mediating the overexpression of these genes (Fig 5A).
Next, we also investigate the effect of CeO2NPs on iPVEC-induced macrophage polariza-
tion. iPVEC were incubated with CeO2NPs for 24h. After medium removal, cells were placed
in DMEM supplemented with 2% FCS for three additional days. Conditioned medium from
CH-iPVEC treated with CeO2NPs significantly increased the levels of arginase-1 on macro-
phages in response to IL-4 treatment, compared with CH-iPVEC treated with vehicle (Fig 5B,
top graph). Additionally, CeO2NPs treatment blocked iNOS overexpression induced by CH-
iPVEC conditioned medium to a similar level to that obtained by the CT-iPVEC condition
upon IFN-γ stimulation (Fig 5B, bottom graph). Therefore, CeO2NPs treatment potentiates
macrophage M2 polarization through changes on the CH-iPVEC secretome.
Cirrhotic rats treated chronically with CeO2NPs down-regulated IL-6
expression in portal vein
As showed above, CeO2NP treatment can modify the expression of certain genes in iPVECs in
vitro. Therefore, we next assessed whether the chronic treatment of rats with CeO2NPs also
has an effect on the portal vein through the modification of its gene expression pattern. To this
aim, we quantified the expression of the same genes that were differentially expressed in CH-
iPVECs after CeO2NPs treatment, IL-6 and TIMP-2. As shown in Fig 5C (right graph), TIMP-
2 showed similar expression levels in the portal vein of control and cirrhotic rats regardless of
the CeO2NPs treatment. Interestingly and in agreement with the in vitro experiments, the
treatment of cirrhotic rats with CeO2NPs significantly downregulated IL-6 in portal vein, com-
pared with vehicle treated rats (Fig 5C, left graph). These results demonstrated the in vivo util-
ity of CeO2NPs treatment for modulating the pathological phenotype of the vasculature in
chronic liver disease.
Discussion
Our results describe for the first time that the endothelium of the portal vein from cirrhotic
rats has pro-inflammatory properties, which are the overexpression of IL-6 and the induction
of M1 macrophage polarization. We showed that an excess of ROS is responsible of this vascu-
lar alteration associated with cirrhosis because the treatment with the CeO2 antioxidant nano-
particles reverts this pro-inflammatory phenotype.
The term ROS includes free radicals and strong oxidants such as superoxide anion radical
(�O2
-), hydroxyl radical (HO�), hydrogen peroxide (H2O2) and hypochlorous acid (HOCl), all
of them being highly reactive. When ROS levels exceed cellular antioxidant defenses oxidative
ranging from m/z 7,2 kDa to m/z 8,6 kDa (n = 3). B Bone marrow derived macrophages (BMDM) were incubated with conditioned
medium from either CT-PVEC (CT-CM) or CH-PVEC (CH-CM). Panel shows gene expression levels for the different genes analyzed.
mRNA levels are illustrated as fold change relative to HPRT mRNA levels �p<0.01 vs CT-CM (n = 10). C BMDM were incubated with
CT-CM or CH-CM and simultaneously with either IL-4 or IFN-γ for 8h (10ng/mL). Panels show iNOS and TNF-α gene expression after
IFN-γ treatment and arginase-1 (Arg1) after IL-4 treatment. �p<0.01 vs. CT-CM, #p<0.01 vs. CT-CM treated with IL-4 or INF-γ (n = 10).
https://doi.org/10.1371/journal.pone.0218716.g004
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Fig 5. CeO2NPs treatment modified the altered gene expression pattern of CH-PVEC and portal vein from cirrhotic rats and
potentiates macrophage M2 polarization. A CT-iPVECs and CH-iPVECs were incubated with vehicle or 1μg/mL CeO2NPs for 24h.
Cells were lysed in trizol and mRNA levels of IL-6 (left graph) and TIMP2 (right graph) were quantified by real-time PCR. mRNA levels
are illustrated as fold change relative to HPRT mRNA levels. �p<0.05 vs CH-PVEC without CeO2NPs (n = 5). B BMDM were incubated
with CT-CM or CH-CM from iPVEC treated with CeO2NPs (1μg/mL) for 24h or vehicle and stimulated simultaneously with either IL-4
or IFN-γ 10ng/mL for 8h. Top graph shows arginase-1 gene expression after IL-4 stimulation and bottom graph shows iNOS gene
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damage develops within the cells promoting molecular damage in DNA, lipids and proteins.
The presence of oxidative stress has been described in most of the clinical conditions associ-
ated with liver fibrosis and portal hypertension as well as in experimental models of liver injury
(NASH, HCV, alcoholic liver cirrhosis, hemochromatosis, Wilson’s disease, primary biliary
cirrhosis, cholestasis, cirrhosis induced by CCl4 in rodents, and bile duct ligation in rodents).
Concurrently, the association between high levels of oxidative stress and a reduction of antiox-
idant defenses has also been reported in the same or similar pathological situations [27,28].
Several strategies have been investigated to diminish ROS damage such as the transduction of
the liver of cirrhotic rats with adenovirus encoding for SOD, which resulted in a significant
improvement of portal pressure [29]. In the same experimental model, hesperidin -an antioxi-
dant bioflavonoid- also ameliorates liver damage through the inhibition of oxidative stress
[30]. In addition, Bataller et al. demonstrated that NADPH oxidase is present in activated
HSCs and generate ROS in an angiotensin II dependent way. The link between NADPH oxi-
dase activity and fibrosis was further demonstrated in vivo in mice lacking a functional
NADPH oxidase [31]. All these studies highlight the need of targeting hepatic oxidative stress
in cirrhotic livers. However, studies investigating the pathological role plaid by ROS in the por-
tal vein of patients or animal models with chronic liver disease are still lacking.
In other pathological contexts, several authors have described the vascular endothelium as
one of the most sensitive targets for oxidative stress. Endothelial activation caused by ROS
exposure is a feature of several dysfunctions including diabetes, vascular toxicity, hypertension,
ischemia, inflammation, acute and chronic tissue injury, atherosclerosis and hypertension
[32–35]. Some of the genes modulated by ROS in these disease scenarios are endothelin-1 [23],
pro-inflammatory mediators such as IL-6 [24] and vascular remodeling factors such as colla-
gen 1 [25,26]. In agreement with these studies, we found these genes overexpressed in portal
vein from cirrhotic rats together with MMP-2, TIMP-1, TIMP-2 and PlGF. The expression
profile found in the immortalized PVECs from cirrhotic rats was quantitatively similar com-
pared to whole portal vein tissue. The only difference was found in the expression of the
MMP-2 gene, which was decreased in CH-PVEC, compared to CT-PVEC. This discrepancy
could be attributed to the fact that whole portal vein extracts contain mRNA from other cell
types, apart from endothelial cells, that may contribute to the overall mRNA expression differ-
ences. Despite this punctual difference, the use of iPVECs in our study has proven to be useful
for the study of the portal vein abnormalities occurring in cirrhosis and, additionally, may pro-
vide us with basic scientific understanding of the mechanism leading to endothelial activation.
For instance, the similarity found when comparing the iPVECs and the portal vein transcrip-
tomes suggests that there may be an epigenetic component that maintains the differential
expression despite the elevated number of cellular passages needed to generate the immortal-
ized PVECs. Yet being a suggestive hypothesis, we need further investigation to confirm this
link. As a downside of using the iPVECs cell line, we have observed negligible eNOS gene
expression in all the cellular clones established. This phenomenon has previously described by
others in the context of later culture passages of endothelial cells [36]. Therefore, and despite
that the iPVECs still conserved other endothelial cells markers, some endothelial functions
may be lost in the iPVECS. This drawback should be kept in mind when interpreting the data
obtained in this cellular model of portal vein endothelium.
expression after IFN-γ stimulation. mRNA levels are illustrated as fold change relative to HPRT mRNA levels. �p<0.05 vs. their
corresponding CeO2NPs-untreated control groups (n = 10). C Portal veins from either control or cirrhotic rats treated i.v. with vehicle or
0.1 mg/kg CeO2NPs for 2 weeks were extracted and lysed in trizol. mRNA expression was analyzed by real-time PCR and represented as
fold change relative to HPRT mRNA levels. �p<0.05 vs. its corresponding CeO2NPs-untreated control group (n = 5).
https://doi.org/10.1371/journal.pone.0218716.g005
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CeO2NP has caught considerable attention as a potential therapeutic tool in the prevention
and treatment of oxidative stress related diseases. This interest relies on the expected properties of
this nanomaterial to scavenge most of the ROS due to its multi-enzyme mimetic activities that
resemble the mechanism of SOD, catalase and peroxidase enzymes [37,38]. The beneficial effects
of CeO2 treatment have been reported in the fields of neurology [39–41], diabetes [42,43], retinal
diseases [44,45], chronic inflammation [38,46], gastrointestinal epithelium inflammation [47],
hepatoprotection against monocrotaline [48], liver cirrhosis [20] and cancer [47,49].
Consistently with these publications, we demonstrated that CeO2NPs treatment was effec-
tive in reducing the proinflammatory state of endothelial cells from the portal vein of cirrhotic
rats. The main feature of this beneficial effect was the downregulation of IL-6 expression in
both cultured PVEC and portal vein from cirrhotic rats. The similar responses observed in the
in vitro studies with isolated endothelial cells and the in vivo models seem to indicate of the
efficient targeting of the CeO2NPs to the cells of interest after i.v. administration. One of the
potential explanations of these results is that the structural alterations in blood vessels occur-
ring during inflammation enhanced CeO2NPs vascular uptake. Increased ROS contribute to
vascular injury by promoting abnormal vascular cell growth, disruption of inner endothelial
cell monolayer integrity and extracellular matrix remodelling [50,51]. These vascular abnor-
malities can be summarized as an increased roughness of the inner vascular layer, loss of the
cobblestone endothelial structure and increased extracellular cell adhesion to the vasculature,
in contrast to the uniform endothelial lining characteristic of the portal vein from control rats.
Interestingly, the treatment of cirrhotic rats with CeO2NPs resulted in the correction of these
morphological alterations. Despite that CeO2NPs flow modes in the blood stream are still a
subject of debate [52,53], it is reasonable to hypothesize that CeO2NPs will be preferentially
retained in rough and porous surfaces rather than in smooth and tight ones, promoting thus
the passive targeting of CeO2NPs in the region of interest.
Many studies have reported high levels of the proinflammatory cytokine IL-6 in experimen-
tal models and patients with liver cirrhosis [54–58]. In addition, it has been proposed a link
between high concentration of IL-6 and HCC [59,60]. Therefore, it is conceivable that the
anti-inflammatory phenotype caused by CeO2 in the portal vein of cirrhotic rats could contrib-
ute to an improvement in liver function. We characterized further this anti-inflammatory
effect by studying the polarization of the macrophages when they interact with CT-iPVECs or
CH-iPVECs. The current model of macrophage polarization proposes two major populations
of macrophages: M1 macrophages, which produce proinflammatory cytokines, ROS, which
are prominently proinflammatory, and M2 macrophages, which promote tissue repair and
stimulate vascular growth. M1-polarized macrophages express IL-1, TNF, IL-6, IL-12, IL-23,
and iNOS in response to INF-γ; whereas M2 macrophages express IL-10, Decoy IL-1RII, IL-
1ra and arginase in response to IL4. We showed that macrophages incubated with conditioned
medium from CH-iPVEC were skewed to an M1 phenotype. In addition, the stimulation of
macrophages with either IFN-γ or IL4 in the presence of conditioned medium from CH-PVEC
potentiated M1 polarization and inhibited M2 polarization, respectively. Noteworthy, CH-
iPVECs pre-treated with CeO2NPs lost their ability to potentiate M1 polarization while pro-
moting a M2-like phenotype in macrophages. The implications of these results are encourag-
ing. For instance, it has recently been reported that fibrosis improves with the injection of BM-
derived macrophages. However it has not been determined whether macrophage polarization
could influence the outcome of this treatment [55]. Therefore, it is reasonable to speculate that
an anti-inflammatory/remodeling phenotype of therapeutic macrophages would be beneficial,
given that exacerbated inflammation contributes to the perpetuation of liver damage. In this
context, the results of our study suggest that the combination of CeO2NPs with cell therapy is
worth to evaluate in the context of chronic liver diseases.
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Some of the advantages of using CeO2 nanomaterials over the traditional antioxidative
drugs are: 1) the multi-enzyme mimetic activities of CeO2NPs, which targets several sources of
ROS generation and 2) the continuous regeneration of the CeO2NPs catalytic activity, which
avoids the exhaustion of its anti-oxidative properties [61]. However, a big effort in standardiza-
tion is still needed for the field to progress. In contrast to the soluble drugs used in clinics for
which optimal dosages are determined in traditional toxicology studies, the therapeutic effi-
cacy of the CeO2NPs does not depend exclusively of the dose. We should also consider other
properties such as shape, density, surface area, size and physical-chemical properties of the
nanoparticle in solution. Changes in these features may affect the catalytic activity and solubil-
ity of the nanoparticle [62,63]. Therefore, these parameters have to be properly tuned and stan-
dardized among different laboratories before this therapeutic strategy can be translated into
the clinical area.
Supporting information
S1 Fig. Characterization of CH-PVEC gene expression pattern after CeO2NPs treatment.
CT-iPVECs and CH-iPVECs were incubated with vehicle or 1μg/mL CeO2NPs for 24h. Cells
were lysed in trizol and mRNA levels of Col1A1, endothelin-1, TIMP1, PlGF and MMP2, were
quantified by real-time PCR. mRNA levels are illustrated as fold change relative to HPRT
mRNA levels (n = 5).
(TIF)
S1 File. Gel raw images. VE-Cadherin gel raw images: upper image shows VE-Cadherin west-
ern blot and lower image the ponceau staining.
(TIF)
S2 File. ARRIVE Guidelines checklist. Document that aims to improve experimental report-
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